← Amneal Pharmaceuticals, Inc.
| Annual Trend | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income (loss) | $169.3m | ($201.3m) | ($603.6m) | $68.6m | $20.2m | ($254.8m) | ($48.7m) | ($73.9m) | $127.9m | |
| Depreciation and amortization | $45.9m | $137.4m | $207.2m | $235.4m | $233.4m | $240.2m | $229.4m | $236.2m | $223.6m | |
| Amortization of debt issuance costs and discount | — | — | — | $8.7m | $9.2m | $8.6m | $8.2m | $29.1m | $22.4m | |
| Intangible asset impairment charges | $0 | $47.1m | $172.8m | $37.3m | $23.4m | $24.1m | $66.9m | $920k | $22.8m | |
| Unrealized foreign currency (gain) loss | ($30.8m) | $18.6m | $7.3m | ($16.7m) | $175k | $15.2m | ($768k) | $7.2m | ($7.5m) | |
| Reclassification of cash flow hedge | — | — | — | — | — | $0 | ($3.4m) | ($26.2m) | $1.2m | |
| Loss on refinancing | $2.5m | $19.7m | $0 | $0 | $0 | $291k | $40.8m | $0 | $31.4m | |
| Change in fair value of contingent consideration | — | — | $0 | $0 | $200k | $731k | ($14.5m) | ($930k) | $0 | |
| Stock-based compensation | $0 | $167.6m | $21.7m | $20.8m | $28.4m | $31.8m | $26.8m | $27.8m | $32.0m | |
| Inventory provision | $3.8m | $44.5m | $82.2m | $75.2m | $54.7m | $51.1m | $74.7m | $96.6m | $86.0m | |
| Other operating charges and credits, net | $9.9m | ($1.9m) | $7.3m | $11.8m | $5.6m | $8.8m | $9.9m | $2.5m | $4.7m | |
| Trade accounts receivable, net | $35.3m | $89.1m | ($132.7m) | $16.8m | ($23.6m) | ($79.7m) | $126.3m | ($162.6m) | ($120.6m) | |
| Inventories | ($31.8m) | ($42.0m) | ($20.4m) | ($113.8m) | ($49.0m) | ($102.4m) | ($126.2m) | ($130.5m) | ($87.0m) | |
| Prepaid expenses, other current assets and other assets | ($25.3m) | $8.8m | $38.9m | $33.3m | ($22.0m) | $9.9m | $37.8m | ($959k) | ($19.2m) | |
| Related party receivables | ($5.5m) | $10.9m | ($939k) | $412k | $7.3m | $646k | ($490k) | $482k | ($13k) | |
| Accounts payable, accrued expenses and other liabilities | $18.1m | ($53.5m) | ($10.3m) | $307k | ($43.9m) | $109.6m | ($94.4m) | $235.1m | $21.3m | |
| Related party payables | $8.2m | ($14.1m) | $5.2m | $1.6m | ($2.4m) | $2.1m | $9.8m | $54.4m | $931k | |
| Acquisition of intangible assets | ($19.5m) | ($14.0m) | ($50.2m) | ($4.3m) | ($1.7m) | ($41.8m) | ($22.4m) | ($14.7m) | ($15.5m) | |
| Proceeds from sale of subsidiary | — | — | — | — | — | $0 | $0 | $12.0m | $0 | |
| Borrowings on revolving credit facility | — | — | — | $0 | $0 | $85.0m | $219.0m | $48.0m | $218.0m | |
| Proceeds from exercise of stock options | $0 | $3.8m | $1.4m | $321k | $853k | $662k | $451k | $1.2m | $2.0m | |
| Employee payroll tax withholding on restricted stock unit and performance stock unit vesting | $0 | $0 | ($926k) | ($863k) | ($2.7m) | ($3.6m) | ($2.4m) | ($8.0m) | ($22.3m) | |
| Tax and other distributions to non-controlling interests | $0 | ($35.5m) | ($13.5m) | ($3.2m) | ($57.1m) | ($17.6m) | ($70.9m) | ($19.8m) | ($43.8m) | |
| Payment of principal on notes payable - related party | $0 | ($92.0m) | $0 | $0 | ($1.0m) | $0 | $0 | ($44.2m) | $0 | |
| Proceeds from alliance party | — | — | — | — | — | — | $0 | $0 | $6.4m | |
| Long-term restricted cash included in other assets - end of period | — | — | — | — | — | — | $0 | $0 | $2.1m | |
| Payable for acquisition of product rights and licenses | — | — | $0 | $0 | $300k | $0 | $2.1m | $3.9m | $8.6m | |
| Loan for land purchase - related party | — | — | — | — | — | — | $0 | $0 | $476k | |
| Net cash provided by operating activities | $234.2m | $250.2m | $1.7m | $379.0m | $241.8m | $65.1m | $345.6m | $295.1m | $340.0m | |
| Purchases of property, plant and equipment | ($94.8m) | ($83.1m) | ($47.2m) | ($56.4m) | ($47.7m) | ($46.4m) | ($43.2m) | ($51.9m) | ($70.1m) | |
| Deposits for future acquisition of property, plant, and equipment | $0 | $0 | $0 | ($5.4m) | ($3.2m) | ($2.4m) | ($3.6m) | ($8.4m) | ($28.8m) | |
| Proceeds from sale of property, plant, equipment and other | $0 | $25.3m | $0 | $0 | $5.0m | $1.0m | $0 | $0 | $2.1m | |
| Net cash used in investing activities | ($98.6m) | ($396.4m) | ($19.6m) | ($317.5m) | ($194.2m) | ($174.3m) | ($69.2m) | ($63.0m) | ($112.3m) | |
| Proceeds from issuance of debt | $250.0m | $1.3b | $0 | $180.0m | $0 | $0 | $217.7m | $0 | $2.7b | |
| Payments of principal on debt, revolving credit facility, financing leases and other | — | — | — | ($35.9m) | ($78.1m) | ($123.3m) | ($414.1m) | ($188.9m) | ($2.8b) | |
| Payments of deferred financing, refinancing costs and debt extinguishment costs | — | — | — | — | — | ($1.7m) | ($162.4m) | ($71k) | ($75.0m) | |
| Net cash used in financing activities | ($95.0m) | $287.7m | ($45.8m) | $131.8m | ($138.1m) | ($106.6m) | ($212.6m) | ($211.8m) | ($31.5m) | |
| Effect of foreign exchange rate on cash | ($242k) | ($670k) | ($2.2m) | $1.0m | $102k | ($5.7m) | $65k | ($999k) | ($1.7m) | |
| Net increase in cash, cash equivalents, and restricted cash | $40.4m | $140.9m | ($66.0m) | $194.3m | ($90.4m) | ($221.5m) | $63.9m | $19.3m | $194.5m | |
| Cash, cash equivalents, and restricted cash - beginning of period | $77.9m | $218.8m | $152.8m | $347.1m | $256.7m | $35.2m | $99.1m | $118.4m | $312.9m | |
| Cash and cash equivalents - end of period | $74.2m | $213.4m | $151.2m | $341.4m | $247.8m | $26.0m | $91.5m | $110.6m | $282.0m | |
| Restricted cash - end of period | $3.8m | $5.4m | $1.6m | $5.7m | $8.9m | $9.3m | $7.6m | $7.9m | $28.8m | |
| Cash paid for interest | $65.1m | $131.5m | $158.6m | $130.2m | $121.7m | $142.7m | $192.8m | $263.5m | $197.8m | |
| Cash paid, net for income taxes | ($5.8m) | $35.0m | $10.3m | $100.1m | ($15.6m) | ($12.6m) | ($2.5m) | $15.2m | $21.3m |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.